Status:
UNKNOWN
The Effect of PERT on Patients Undergoing Pancreaticoduodenectomy
Lead Sponsor:
Ruijin Hospital
Conditions:
Pancreatic Exocrine Insufficiency
Pancreatic Enzyme Replacement Therapy
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
A comprehensive perioperative nutrition management plan for pancreaticoduodenectomy, primarily based on pancreatic enzyme replacement therapy (PERT). A prospective randomized controlled study was cond...
Eligibility Criteria
Inclusion
- Gender unlimited, 18-80 years old;
- Patients undergoing pancreaticoduodenectomy due to various benign or malignant diseases;
- Voluntary testing with informed consent.
Exclusion
- Pregnant women and lactating women
- Patients with distant metastasis based on tumor staging before surgery;
- Tumor recurrence;
- Refuse to sign the consent form.
Key Trial Info
Start Date :
November 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06119880
Start Date
November 1 2023
End Date
December 31 2025
Last Update
November 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Ruijin Hospital
Shanghai, Shanghai Municipality, China, 200025